Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate
Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.
STAT4h
The view from overseas on tumult in U.S. science
Happy V-Day! Gorge on heart-shaped chocolate and ponder the implications of RFK Jr. being sworn in as health secretary. Today, we talk about that, as well as new cancer data from Corbus Pharma, Europe ...
RBC Capital Sticks to Its Buy Rating for Corbus Pharmaceuticals (CRBP)
In a report released on February 11, Brian Abrahams from RBC Capital maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research ...
Corbus Pharmaceuticals falls after trial data for lead asset
Corbus Pharmaceuticals (CRBP) stock drops 12% after mixed Phase 1 trial results for its lead cancer candidate. Read more here.
Corbus Pharmaceuticals announces data from its US, UK study of CRB-701
Corbus Pharmaceuticals (CRBP) announced that data from its US and UK conducted first-in-human dose escalation clinical study of CRB-701 is ...
What is HC Wainwright’s Forecast for CRBP FY2029 Earnings?
Analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Corbus Pharmaceuticals in a note issued to investors on Monday, February 10th. HC Wainwright analyst A. Maldonado expects ...
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day
Shares of Corbus Pharmaceuticals Holdings Inc. CRBP rallied 5.10% to $9.48 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the NA ...
H.C. Wainwright maintains $75 target on Corbus stock
H.C. Wainwright analyst Andres Y. Maldonado confirmed a Buy rating and a $75.00 price target on Corbus Pharmaceuticals (NASDAQ:CRBP), representing significant upside potential from the current price ...